<DOC>
	<DOCNO>NCT03056742</DOCNO>
	<brief_summary>This study conduct extension phase II clinical trial SRPL/CLI/10-11/001 ( NCT01484574 ) . The CDSCO recommend flexibility continue clinical study consultation ICMR , per recommendation Cellular biology base therapeutic drug evaluation committee ( CBBTDEC ) .</brief_summary>
	<brief_title>A Clinical Trial Study Efficacy Safety Stempeucel® Patients With CLI Due Buergers Disease</brief_title>
	<detailed_description>This study evaluate safety efficacy intramuscular injection stempeucel ( R ) ( Ex vivo culture adult bone marrow derive allogeneic mesenchymal stem cell ) Critical Limb Ischemia due Buerger 's Disease</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Thromboangiitis Obliterans</mesh_term>
	<criteria>1 . Buerger 's disease diagnose Shionoya criterion 2 . Males female ( willing use accept method contraception course study ) age group 1865 yr . 3 . Established CLI study limb , clinically hemodynamically confirm per Rutherford III5 ; 4 . Patients Rutherford III6 gangrene extend maximally head metatarsal limit toe ( patient wet gangrene must undergo wound debridement / amputation screen ) . 5 . Patients infrapopliteal occlusive disease rest pain ischemic ulcer/necrosis ( patient least one measureable ulcer ) , eligible fail traditional revascularization treatment per investigator judgment ( No option patient ) . 6 . ABPI ≤ 0.6 ankle pressure ≤ 50 mm Hg . 7 . Patients able understand requirement study , willing provide voluntary write informed consent video consent , abide study requirement , agree return require followup visit . 1 . Patients CLI indicate major amputation screen 2 . Atherosclerotic PAD 3 . Ulcers exposure tendon and/bone shin region . 4 . Previous trans metatarsal amputation study limb 5 . Any Lumbar sympathectomy procedure perform less 90 day prior screen 6 . Patients gait disturbance reason CLI 7 . Diagnosis diabetes mellitus ( type 1 type 2 ) 8 . Patients leave ventricular ejection fraction &lt; 35 % 9 . Patients suffer clinically relevant peripheral neuropathy 10 . History stroke myocardial infarction 11 . Patients contraindicate MRA 12 . Patients DVT limb . 13 . Patients clinically serious and/or unstable intercurrent infection , medical illness condition uncontrolled whose control , opinion Investigator , may jeopardize participation study complication therapy 14 . Documented terminal illness cancer concomitant disease process life expectancy &lt; 1 year 15 . Patients already enrol another investigational drug trial complete within 3 month receive stem cell past 16 . Patient known hypersensitivity constituent stempeucel® dimethyl sulfoxide ( DMSO ) human serum albumin ( HSA ) 17 . History severe alcohol drug abuse within 3 month screen 18 . Hb % &lt; 10 gm % male , Hb % &lt; 9 gm % female , serum creatinine ≥ 2mg % , serum Total Bilirubin ≥2mg % 19 . Pregnant lactate woman 20 . Patients test positive HIV 1 &amp; 2 , HCV , HBV , CMV , RPR antibodies HBsAg antigen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>